A phase I, placebo controlled, dose escalation safety and pharmacokinetic study of (Z)-Endoxifen in healthy female volunteers

Trial Profile

A phase I, placebo controlled, dose escalation safety and pharmacokinetic study of (Z)-Endoxifen in healthy female volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2017

At a glance

  • Drugs Endoxifen (Primary) ; Endoxifen (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors Atossa Genetics
  • Most Recent Events

    • 26 Jun 2017 According to an Atossa Genetics media release, company expect to complete enrollment in the next six weeks.
    • 26 Jun 2017 According to an Atossa Genetics media release, topical arm has been fully enrolled and dosed and the first of the three oral cohorts has now been dosed.
    • 26 Jun 2017 According to an Atossa Genetics media release, Independent Safety Committee reviewed the blinded data generated from the first cohort (n=8) and concluded that the study may advance to the next oral dosing level.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top